Further data on neoadjuvant #Immunotherapy #OpenAccess in @JCO_ASCO ➡️ Nivo/Ipi in dMMR/MSI gastric + esophagogastric junction #Cancer ✅32 #patients 🔪29 underwent #surgery 🔥All 29 R0 🔬58,6% pCR (T0N0) @OncoAlert 🚨 @YJanjigianMD @MyriamChalabi Tweet added by Ben Westphalen @BenWestphalen

Ben Westphalen

1 year

Further data on neoadjuvant #Immunotherapy #OpenAccess in @JCO_ASCO ➡️ Nivo/Ipi in dMMR/MSI gastric + esophagogastric junction #Cancer ✅32 #patients 🔪29 underwent #surgery 🔥All 29 R0 🔬58,6% pCR (T0N0) @OncoAlert 🚨 @YJanjigianMD @MyriamChalabi

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch...

PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy...

ascopubs.org